Last reviewed · How we verify
Intravitreal Aflibercept Injection
Aflibercept is a soluble decoy receptor that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with endogenous receptors and reducing abnormal blood vessel growth in the eye.
Aflibercept is a soluble decoy receptor that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with endogenous receptors and reducing abnormal blood vessel growth in the eye. Used for Neovascular (wet) age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.
At a glance
| Generic name | Intravitreal Aflibercept Injection |
|---|---|
| Also known as | IAI, Eylea, Eylea, VEGF Trap-Eye, IAI; EYLEA®; BAY86-5321; VEGF Trap-Eye, Intravitreal Eylea injection |
| Sponsor | Ophthalmic Consultants of Boston |
| Drug class | VEGF inhibitor / Soluble decoy receptor |
| Target | VEGF-A, VEGF-B, PlGF (Placental Growth Factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Aflibercept functions as a fusion protein combining VEGF-binding domains from VEGF receptors 1 and 2 with the Fc portion of human IgG1. When injected intravitreally, it acts as a molecular trap, sequestering circulating VEGF and PlGF in the vitreous and preventing their binding to VEGFR1 and VEGFR2 on endothelial cells. This inhibition of VEGF signaling reduces pathological neovascularization, vascular permeability, and inflammation associated with retinal diseases.
Approved indications
- Neovascular (wet) age-related macular degeneration
- Macular edema following retinal vein occlusion
- Diabetic macular edema
- Diabetic retinopathy
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
Key clinical trials
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) (PHASE2, PHASE3)
- 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (PHASE3)
- High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes (PHASE4)
- Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL (NA)
- Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety (NA)
- COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (PHASE3)
- Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients (EARLY_PHASE1)
- A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: